brain-penetrant LSD1 inh. for neuro. disorders sociability improvement in vivo, completed Ph. I in HV tranylcypromine class mechanism-based inh. Sci. Adv., Mar. 12, 2021 Takeda Pharmaceuticals, Fujisawa, JP